Our advocacy promotes transparency, accountability and the public interest in the field of pharmaceuticals. Our evidence-based advocacy aims to guarantee better and affordable medicines for Europe by questioning and reforming the current pharmaceutical business model and calling for better access to medicines for all.
A series of online, live, public dialogues putting the spotlight on actionable solutions on access to medicines for decision-makers in Europe.
The revision of the EU pharmaceutical legislation: balancing between innovation incentives and access to affordable medicines
Public consultation response highlighting critical aspects for the forthcoming revision of the pharmaceutical legislation.
Speech given by EPHA’s Director General Dr. Milka Sokolović on better access to medicines within the Oslo Medicines Initiative.
EPHA joins calls for enhanced clinical trial transparency and good governance in the European Medicines Agency
EPHA has joined the call led by the European Alliance for Responsible R&D and Affordable Medicines to urge EU Ministers to ensure that the Regulation for a reinforced EMA role leads to enhanced clinical trial transparency and upholds good governance
Analysis & Opinion
European Parliament’s special committee on COVID-19 is an opportunity to drive health equity forward
Examining lessons learned and formulating recommendations for the new COVID committee within the EP.
COVID-19 was a test scenario for how we rise to global threats where the risk and impacts are unequally distributed.